Risk prediction of hyperuricemia based on particle swarm fusion machine learning solely dependent on routine blood tests.

Journal: BMC medical informatics and decision making
PMID:

Abstract

Hyperuricemia has seen a continuous increase in incidence and a trend towards younger patients in recent years, posing a serious threat to human health and highlighting the urgency of using technological means for disease risk prediction. Existing risk prediction models for hyperuricemia typically include two major categories of indicators: routine blood tests and biochemical tests. The potential of using routine blood tests alone for prediction has not yet been explored. Therefore, this paper proposes a hyperuricemia risk prediction model that integrates Particle Swarm Optimization (PSO) with machine learning, which can accurately assess the risk of hyperuricemia by relying solely on routine blood data. In addition, an interpretability method based on Explainable Artificial Intelligence(XAI) is introduced to help medical staff and patients understand how the model makes decisions. This paper uses Cohen's d value to compare the differences in indicators between hyperuricemia and non-hyperuricemia patients and identifies risk factors through multivariate logistic regression. Subsequently, a risk prediction model is constructed based on the parameter optimization of five machine learning models using the PSO algorithm. The accuracy and sensitivity of the proposed particle swarm fusion Stacking model reach 97.8% and 97.6%, marking an improvement in accuracy of over 11% compared to the state-of-the-art models. Finally, a sensitivity analysis of factors affecting the prediction results is conducted using the XAI method. This paper has also developed a Health Portrait Platform that integrates the proposed risk prediction models, enabling real-time online health risk assessment. Since only routine blood test data are used, the new model has better feasibility and scalability, providing a valuable reference for assessing the risk of hyperuricemia occurrence.

Authors

  • Min Fang
    Department of Clinical Laboratory, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China.
  • Chengjie Pan
    School of Information Science and Technology, Hangzhou Normal University, Yuhangtang Rd., Hangzhou, Zhejiang, 311121, China.
  • Xiaoyi Yu
    College of Engineering, Zhejiang University, Yuhangtang Rd., Hangzhou, Zhejiang, 310058, China.
  • Wenjuan Li
    Faculty of Chemistry and Material Science, Langfang Normal University, Langfang 065000, Hebei, China.
  • Ben Wang
    Department of Mechanical and Automation Engineering, The Chinese University of Hong Kong, Shatin N.T., Hong Kong, China.
  • Huajian Zhou
    Hangzhou B-Soft Co Ltd, Zhejiang Province, Hangzhou, 310052, China.
  • Zhenying Xu
    Qingdao Medical College, Qingdao University, Qingdao, Shandong, China.
  • Genyuan Yang
    School of Information Science and Technology, Hangzhou Normal University, Yuhangtang Rd., Hangzhou, Zhejiang, 311121, China.